Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia

Fig. 2

Rheb1 deletion prolongs the survival of AML mice. a Experimental scheme of the Rheb1-deficient MLL-AF9 mouse model. b The survival curve of Rheb1 fl/fl and Rheb1 Δ/Δ AML mice using Kaplan-Meier analysis (n = 11). Approximately 5 × 105 P1 GFP+ cells from the two groups were transplanted into sublethally irradiated recipient mice (P2). c The survival curve of Rheb1 fl/fl and Rheb1 Δ/Δ AML mice calculated using Kaplan-Meier analysis (n = 6). Approximately 1 × 106 P2 GFP+ cells obtained from the two groups were transplanted into sublethally irradiated recipient mice (P3). d The number of white blood cells (WBC) in PB (n = 4). e The number of platelets (PLT) in PB (n = 4). PB samples were obtained from AML mice when Rheb1 fl/fl GFP+ cells in PB was approximately 80 %. fh The percentage of GFP+ cells in the PB (f), BM (g), and spleen (h) of Rheb1 fl/fl and Rheb1 Δ/Δ AML mice by FACS analysis (n = 4). i The spleen size (left) and spleen weight to body weight ratio of Rheb1 fl/fl and Rheb1 Δ/Δ AML mice (right). All experiments were performed at least three times. The values in the panels represent the mean numbers ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001

Back to article page